NE 1530

Drug Profile

NE 1530

Latest Information Update: 01 Nov 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neose Technologies
  • Class Carbohydrates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Otitis media

Most Recent Events

  • 01 Nov 2000 Results of a clinical study have been added to the Bacterial infections therapeutic trials section
  • 21 Dec 1999 Discontinued-I for Otitis media in USA (Unknown route)
  • 21 Dec 1999 Discontinued-II for Otitis media in Finland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top